{"id":104236,"date":"2026-01-07T11:06:36","date_gmt":"2026-01-07T16:06:36","guid":{"rendered":"https:\/\/www.businessupturn.com\/usa\/?p=104236"},"modified":"2026-01-07T10:55:33","modified_gmt":"2026-01-07T15:55:33","slug":"fibrogen-rebrands-as-kyntra-bio-shares-rise","status":"publish","type":"post","link":"https:\/\/www.businessupturn.com\/usa\/fibrogen-rebrands-as-kyntra-bio-shares-rise\/104236\/","title":{"rendered":"FibroGen rebrands as Kyntra Bio, shares rise"},"content":{"rendered":"<div class=\"flex flex-col text-sm\">\n<article class=\"text-token-text-primary w-full focus:outline-none [--shadow-height:45px] has-data-writing-block:pointer-events-none has-data-writing-block:-mt-(--shadow-height) has-data-writing-block:pt-(--shadow-height) [&:has([data-writing-block])>*]:pointer-events-auto scroll-mt-[calc(var(--header-height)+min(200px,max(70px,20svh)))]\" dir=\"auto\" data-turn-id=\"request-WEB:333299d9-4791-462f-8073-1524a96232a8-27\" data-testid=\"conversation-turn-18\" data-scroll-anchor=\"true\" data-turn=\"assistant\">\n<div class=\"text-base my-auto mx-auto pb-10 [--thread-content-margin:--spacing(4)] @w-sm\/main:[--thread-content-margin:--spacing(6)] @w-lg\/main:[--thread-content-margin:--spacing(16)] px-(--thread-content-margin)\">\n<div class=\"[--thread-content-max-width:40rem] @w-lg\/main:[--thread-content-max-width:48rem] mx-auto max-w-(--thread-content-max-width) flex-1 group\/turn-messages focus-visible:outline-hidden relative flex w-full min-w-0 flex-col agent-turn\">\n<div class=\"flex max-w-full flex-col grow\">\n<div class=\"min-h-8 text-message relative flex w-full flex-col items-end gap-2 text-start break-words whitespace-normal [.text-message+&]:mt-1\" dir=\"auto\" data-message-author-role=\"assistant\" data-message-id=\"0432e071-ed16-4b7a-a83f-1b812d830245\" data-message-model-slug=\"gpt-5-2\">\n<div class=\"flex w-full flex-col gap-1 empty:hidden first:pt-[1px]\">\n<div class=\"markdown prose dark:prose-invert w-full break-words dark markdown-new-styling\">\n<p data-start=\"50\" data-end=\"192\">FibroGen shares climbed about 5 percent on Wednesday. The move followed the company\u2019s announcement that it will change its name to Kyntra Bio.<\/p>\n<p data-start=\"194\" data-end=\"311\">The rebranding reflects a sharper focus on cancer and rare disease treatments. The company is based in San Francisco.<\/p>\n<p data-start=\"313\" data-end=\"483\">FibroGen said its stock will trade under a new ticker symbol. The new Nasdaq symbol will be KYNB. Trading under the new name will begin at market open on January 8, 2026.<\/p>\n<p data-start=\"485\" data-end=\"623\">CEO Thane Wettig called 2025 a transformational year for the company. He said the new name better represents how the business has evolved.<\/p>\n<p data-start=\"625\" data-end=\"750\">Wettig said Kyntra Bio reflects a clear mission. The company wants to create meaningful impact for patients and shareholders.<\/p>\n<p data-start=\"752\" data-end=\"939\">The company highlighted several major changes made in 2025. It sold its China business. It also paid off its senior secured term loan. These moves helped extend its cash runway into 2028.<\/p>\n<p data-start=\"941\" data-end=\"1098\">Going forward, Kyntra Bio will focus on its mid and late stage drug programs. One key asset is FG 3246. This is an antibody drug conjugate that targets CD46.<\/p>\n<p data-start=\"1100\" data-end=\"1221\">Another important program is FG 3180. This is a PET imaging agent. It is currently in Phase 2 trials for prostate cancer.<\/p>\n<p data-start=\"1223\" data-end=\"1393\">The company also shared updates on roxadustat. This drug is ready for Phase 3 studies. It recently received Orphan Drug status from the FDA for myelodysplastic syndromes.<\/p>\n<p data-start=\"1395\" data-end=\"1613\">Topline data from a Phase 1b and Phase 2 study of FG 3246 combined with enzalutamide is expected in the first quarter of 2026. Interim results from its Phase 2 monotherapy study are expected in the second half of 2026.<\/p>\n<p data-start=\"1615\" data-end=\"1681\" data-is-last-node=\"\" data-is-only-node=\"\">The company said the name change will not affect its CUSIP number.<\/p>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/article>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>FibroGen shares climbed about 5 percent on Wednesday. The move followed the company\u2019s announcement that it will change its name\u2026<\/p>\n","protected":false},"author":294,"featured_media":104237,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[73],"tags":[34817,34818],"class_list":["post-104236","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-us-markets","tag-fibrogen","tag-kyntra-bio"],"reading_time":"2 min read","_links":{"self":[{"href":"https:\/\/www.businessupturn.com\/usa\/wp-json\/wp\/v2\/posts\/104236","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.businessupturn.com\/usa\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.businessupturn.com\/usa\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.businessupturn.com\/usa\/wp-json\/wp\/v2\/users\/294"}],"replies":[{"embeddable":true,"href":"https:\/\/www.businessupturn.com\/usa\/wp-json\/wp\/v2\/comments?post=104236"}],"version-history":[{"count":0,"href":"https:\/\/www.businessupturn.com\/usa\/wp-json\/wp\/v2\/posts\/104236\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.businessupturn.com\/usa\/wp-json\/wp\/v2\/media\/104237"}],"wp:attachment":[{"href":"https:\/\/www.businessupturn.com\/usa\/wp-json\/wp\/v2\/media?parent=104236"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.businessupturn.com\/usa\/wp-json\/wp\/v2\/categories?post=104236"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.businessupturn.com\/usa\/wp-json\/wp\/v2\/tags?post=104236"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}